No­var­tis nabs FDA ap­proval for hyped Eylea ri­val

6 years ago
R&D

No­var­tis con­fi­dent­ly breaks out mid-stage da­ta on Xo­lair com­peti­tor

6 years ago
R&D

NGM Bio un­veils pos­i­tive PhII NASH re­sults to some unim­pressed in­vestors

6 years ago
R&D

DB­V's peanut al­ler­gy patch is fi­nal­ly un­der FDA re­view; Rit­ter swal­lows bit­ter pill to ex­plore strate­gic al­ter­na­tives

6 years ago
News Briefing

Acor­da los­es its last shot at pro­tect­ing its cash cow fran­chise drug. It’s up to In­bri­ja now

6 years ago
R&D

Gilead chief O'­Day re­cruits top Genen­tech re­searcher as new CMO in the wake of a high-lev­el R&D ex­o­dus

6 years ago
People
R&D

Pfiz­er fronts $250M to nab an­ti­sense drug from Akcea/Io­n­is in up to $1.5B deal

6 years ago
Deals
R&D

Trio wins No­bel Prize for Med­i­cine for 'fun­da­men­tal' dis­cov­ery

6 years ago
Discovery

Ness Berming­ham looks to lead the wave of RNA edit­ing at new At­las up­start Ko­r­ro Bio

6 years ago
Startups
Cell/Gene Tx

Dif­ferin mak­er Gal­der­ma wins FDA ap­proval for a new retinoid for ac­ne

6 years ago
Pharma
FDA+

We’ll see this week if the pub­lic mar­kets’ love af­fair with biotech uni­corns is still run­ning hot — or not

6 years ago
Financing

An­ti­body re­search grad­u­ates from a top Ox­ford lab in­to the biotech world — with $34M to fund R&D work

6 years ago
Financing
Startups

Oph­thal­mol­o­gy biotech up­start is ask­ing in­vestors to bet $85M-plus on their late-stage ri­val to Resta­sis and Xi­idra

6 years ago
Financing

J&J poach­es Bay­er ex­ec Jim Swan­son as chief in­for­ma­tion of­fi­cer

6 years ago
People
Pharma

At­las-backed Dyne taps Joshua Brumm as CEO; Sekar Kathire­san woos car­di­ol­o­gist to gene edit­ing start­up

6 years ago
Peer Review

Em­ma Walm­s­ley joins #MeToo­Pay; Monopar post­pones $40M IPO

6 years ago
News Briefing

New NIH vi­ral vec­tor flips the script on sick­le cell dis­ease gene ther­a­py

6 years ago
R&D

Ear­ly func­tion­al da­ta on limb gir­dle pa­tients buoy ex­pec­ta­tions for Sarep­ta's gene ther­a­py

6 years ago
R&D
Cell/Gene Tx

King Keytru­da: Mer­ck­'s PD-1 star scores #1 po­si­tion and $22B+ pre­dic­tion in an­oth­er top 10 block­buster list for 2025

6 years ago
Pharma

Two acute cas­es of liv­er dis­ease in healthy sub­jects kill Ar­bu­tus' hep B pro­gram

6 years ago
R&D

Book ex­cerpt: How Hen­ri Ter­meer built Gen­zyme and pi­o­neered the rare dis­ease in­dus­try

6 years ago
People

Phar­ma to blame for im­peach­ment woes? Yep, Pres­i­dent Trump just sug­gest­ed that about Amer­i­ca's least fa­vorite ...

6 years ago
Pharma

Gilead scores PrEP ap­proval for De­scovy — kick­ing off mar­ket­ing push be­fore Tru­va­da gener­ics swarm

6 years ago
Pharma
FDA+

NICE fails to en­dorse Roche's Tecen­triq for breast can­cer; Eli­cio clos­es fi­nanc­ing round with $33M

6 years ago
News Briefing
First page Previous page 892893894895896897898 Next page Last page
A service from the Financial Times